KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Total Liabilities (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Total Liabilities data on record, last reported at $194.1 million in Q4 2025.

  • For Q4 2025, Total Liabilities rose 20.12% year-over-year to $194.1 million; the TTM value through Dec 2025 reached $194.1 million, up 20.12%, while the annual FY2025 figure was $194.1 million, 20.12% up from the prior year.
  • Total Liabilities reached $194.1 million in Q4 2025 per AQST's latest filing, up from $167.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $194.1 million in Q4 2025 and bottomed at $113.7 million in Q1 2021.
  • Average Total Liabilities over 5 years is $156.5 million, with a median of $162.0 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: soared 44.51% in 2021, then decreased 6.67% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $144.1 million in 2021, then increased by 21.85% to $175.6 million in 2022, then decreased by 6.67% to $163.9 million in 2023, then fell by 1.42% to $161.6 million in 2024, then grew by 20.12% to $194.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $194.1 million in Q4 2025, $167.7 million in Q3 2025, and $166.3 million in Q2 2025.